Urologix (Urologix) Ending Cash Position : $0.49 Mil (As of Mar. 2015)

View and export this data going back to 1996. Start your Free Trial

What is Urologix Ending Cash Position?

Urologix's Ending Cash Position for the quarter that ended in Mar. 2015 was $0.49 Mil.

Urologix's quarterly Ending Cash Position declined from Sep. 2014 ($0.55 Mil) to Dec. 2014 ($0.53 Mil) and declined from Dec. 2014 ($0.53 Mil) to Mar. 2015 ($0.49 Mil).

Urologix's annual Ending Cash Position increased from Jun. 2012 ($1.90 Mil) to Jun. 2013 ($2.29 Mil) but then declined from Jun. 2013 ($2.29 Mil) to Jun. 2014 ($0.72 Mil).

Urologix Ending Cash Position Historical Data

The historical data trend for Urologix's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Urologix Ending Cash Position Chart

Urologix Annual Data

Trend

Jun05

Jun06

Jun07

Jun08

Jun09

Jun10

Jun11

Jun12

Jun13

Jun14

Ending Cash Position

Get a 7-Day Free Trial

5.70

3.06

1.90

2.29

0.72

Urologix Quarterly Data
	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15
Ending Cash Position	Get a 7-Day Free Trial															0.82	0.72	0.55	0.53	0.49

Urologix Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Urologix's Ending Cash Position for the fiscal year that ended in Jun. 2014 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	2.29	+	-1.572
	=	0.72

Urologix's Ending Cash Position for the quarter that ended in Mar. 2015 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	0.53	+	-0.038
	=	0.49

Urologix Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Urologix's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Urologix (Urologix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Urologix Inc (OTCPK:ULGX) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

14405 21st Avenue North, Suite 110, Minneapolis, MN, USA, 55447

Website

http://www.urologix.com

Urologix Inc is a United States-based company engaged in the development, manufacturing, and marketing of minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). The firm markets the Cooled ThermoTherapy (CTC) product line and the Prostiva Radio Frequency (RF) Therapy System (Prostiva). The CTC produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. The Prostiva delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH voiding symptoms. The CTC product line includes the CoolWave and Targis Control Units and the CTC Advance catheter.

Executives

Emery Sidney W Jr	director	C/O QUALIGEN THERAPEUTICS, INC., 2042 CORTE DEL NOGAL, CARLSBAD CA 92011
Patrick D Spangler	director	14405 21ST AVENUE NORTH, MINNEAPOLIS MN 55447
Gregory Fluet	director, officer: CEO	14405 21ST AVENUE NORTH, MINNEAPOLIS MN 55447
William M Moore	director
Guy C Jackson	director	C/O EPICEPT CORPORATION, 777 OLD SAW MILL ROAD, TARRYTOWN NY 10591
Daniel J Starks	director	ONE ST JUDE MEDICAL DRIVE, ST PAUL MN 55117
Claude Tihon	officer: Chief Technology Officer
Bobby Ivan Griffin	director	1326 SPRING VALLEY RD GOLDEN VALLEY PA 55422
David A Montecalvo	officer: VP, Product Dev. & Operations	530 HERMAN O. WEST DRIVE, EXTON PA 19341
Susan Bartlett Foote	director	649 SUMMIT AVENUE, ST PAUL MN 55105